PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

“Bottlebrush” particles deliver big chemotherapy payloads directly to cancer cells

Outfitted with antibodies that guide them to the tumor site, the new nanoparticles could reduce the side effects of treatment.

2025-09-09
(Press-News.org) CAMBRIDGE, MA -- Using tiny particles shaped like bottlebrushes, MIT chemists have found a way to deliver a large range of chemotherapy drugs directly to tumor cells.

To guide them to the right location, each particle contains an antibody that targets a specific tumor protein. This antibody is tethered to bottlebrush-shaped polymer chains carrying dozens or hundreds of drug molecules — a much larger payload than can be delivered by any existing antibody-drug conjugates.

In mouse models of breast and ovarian cancer, the researchers found that treatment with these conjugated particles could eliminate most tumors. In the future, the particles could be modified to target other types of cancer, by swapping in different antibodies.

“We are excited about the potential to open up a new landscape of payloads and payload combinations with this technology, that could ultimately provide more effective therapies for cancer patients,” says Jeremiah Johnson, the A. Thomas Geurtin Professor of Chemistry at MIT, a member of the Koch Institute for Integrative Cancer Research, and the senior author of the new study.

MIT postdoc Bin Liu is the lead author of the paper, which appears today in Nature Biotechnology.

A bigger drug payload

Antibody-drug conjugates (ADCs) are a promising type of cancer treatment that consist of a cancer-targeting antibody attached to a chemotherapy drug. At least 15 ADCs have been approved by the FDA to treat several different types of cancer.

This approach allows specific targeting of a cancer drug to a tumor, which helps to prevent some of the side effects that occur when chemotherapy drugs are given intravenously. However, one drawback to currently approved ADCs is that only a handful of drug molecules can be attached to each antibody. That means they can only be used with very potent drugs — usually DNA-damaging agents or drugs that interfere with cell division.

To try to use a broader range of drugs, which are often less potent, Johnson and his colleagues decided to adapt bottlebrush particles that they had previously invented. These particles consist of a polymer backbone that are attached to tens to hundreds of “prodrug” molecules — inactive drug molecules that are activated upon release within the body. This structure allows the particles to deliver a wide range of drug molecules, and the particles can be designed to carry multiple drugs in specific ratios.

Using a technique called click chemistry, the researchers showed that they could attach one, two, or three of their bottlebrush polymers to a single tumor-targeting antibody, creating an antibody-bottlebrush conjugate (ABC). This means that just one antibody can carry hundreds of prodrug molecules. The currently approved ADCs can carry a maximum of about eight drug molecules.

The huge number of payloads in the ABC particles allows the researchers to incorporate less potent cancer drugs such as doxorubicin or paclitaxel, which enhances the customizability of the particles and the variety of drug combinations that can be used.

“We can use antibody-bottlebrush conjugates to increase the drug loading, and in that case, we can use less potent drugs,” Liu says. “In the future, we can very easily copolymerize with multiple drugs together to achieve combination therapy.”

The prodrug molecules are attached to the polymer backbone by cleavable linkers. After the particles reach a tumor site, some of these linkers are broken right away, allowing the drugs to kill nearby cancer cells even if they don’t express the target antibody. Other particles are absorbed into cells with the target antibody before releasing their toxic payload.

Effective treatment

For this study, the researchers created ABC particles carrying a few different types of drugs: microtubule inhibitors called MMAE and paclitaxel, and two DNA-damaging agents, doxorubicin and SN-38. They also designed ABC particles carrying an experimental type of drug known as PROTAC (proteolysis-targeting chimera), which can selectively degrade disease-causing proteins inside cells.

Each bottlebrush was tethered to an antibody targeting either HER2, a protein often overexpressed in breast cancer, or MUC1, which is commonly found in ovarian, lung, and other types of cancer.

The researchers tested each of the ABCs in mouse models of breast or ovarian cancer and found that in most cases, the ABC particles were able to eradicate the tumors. This treatment was significantly more effective than giving the same bottlebrush prodrugs by injection, without being conjugated to a targeting antibody.

“We used a very low dose, almost 100 times lower compared to the traditional small-molecule drug, and the ABC still can achieve much better efficacy compared to the small-molecule drug given on its own,” Liu says.

These ABCs also performed better than two FDA-approved ADCs, T-DXd and TDM-1, which both use HER2 to target cells. T-DXd carries deruxtecan, which interferes with DNA replication, and TDM-1 carries emtansine, a microtubule inhibitor.

In future work, the MIT team plans to try delivering combinations of drugs that work by different mechanisms, which could enhance their overall effectiveness. Among these could be immunotherapy drugs such as STING activators.

The researchers are also working on swapping in different antibodies, such as antibodies targeting EGFR, which is widely expressed in many tumors. More than 100 antibodies have been approved to treat cancer and other diseases, and in theory any of those could be conjugated to cancer drugs to create a targeted therapy.

###

The research was funded in part by the National Institutes of Health, the Ludwig Center at MIT, and the Koch Institute Frontier Research Program. 

 

END


ELSE PRESS RELEASES FROM THIS DATE:

New AI tool pinpoints genes, drug combos to restore health in diseased cells

2025-09-09
In a move that could reshape drug discovery, researchers at Harvard Medical School have designed an artificial intelligence model capable of identifying treatments that reverse disease states in cells. Unlike traditional approaches that typically test one protein target or drug at a time in hopes of identifying an effective treatment, the new model, called PDGrapher and available for free, focuses on multiple drivers of disease and identifies the genes most likely to revert diseased cells back to healthy function. The ...

Predicting where deadly brain cancer may spread next

2025-09-09
Glioblastoma is a devastatingly effective brain cancer. Doctors can cut it out or blast it with radiation, but that only buys time. The cancer has an insidious ability to hide enough tumor cells in tissue around the tumor to allow it to return as deadly as ever. Patients diagnosed with glioblastoma survive for an average of 15 months. What’s needed is a better way of identifying those hidden cancer cells and predicting where the tumor might grow next. Jennifer Munson believes she and her research team at the Fralin Biomedical Research Institute at VTC have developed a tool to do just that. Their method, described ...

First ever measure of boron in individual cancer cells could revolutionise drug understanding

2025-09-09
A new technique has measured boron in individual cancer cells for the first time, enabling researchers to better understand how drugs act to kill tumours in some cancers.   In a new article in the Journal of Analytical Atomic Spectrometry, a team from the University of Birmingham funded by the Rosetrees Trust have for the first time used a technology to conduct real-time measurement of boron in live tumour cells.  The technique, called single-cell ICP-MS, enabled the team to see how and when treatments for head and neck cancers enter and exit tumour cells.   Boron Neutron Capture Therapy (BNCT) is a new form of therapeutic for head and neck cancer that involves ...

Graz researchers discover what stiffens the aorta

2025-09-09
Cardiovascular diseases remain the most common cause of death worldwide. In Europe, they account for over 40 percent of all deaths. However, known risk factors such as high cholesterol levels or high blood pressure cannot fully explain the high mortality rate or the number of cardiovascular diseases. Scientists in Graz have now investigated a new factor that is closely linked to cardiovascular mortality. Elevated levels of the amino acid homocysteine in the blood led to a stiffer and less elastic aorta in an animal model. These findings contribute to the current understanding ...

Breakthrough in atomic-level etching of hafnium oxide, a promising material for advanced semiconductors

2025-09-09
Hafnium oxide (HfO2) has attracted attention as a promising material for ultrathin semiconductors and other microelectronic devices. The strong ionic bond between hafnium and oxygen atoms in HfO2 gives it a high dielectric constant, superior thermal stability, and a wide band gap. Notably, these properties can be maintained even at the atomic scale. Meanwhile, these properties also pose challenges in achieving highly precise and smooth etching of HfO2 films. Now, a group of researchers from Japan and Taiwan has successfully etched HfO2 films with atomic-level precision, smoothness, ...

How evolution explains autism rates in humans

2025-09-09
A new paper in Molecular Biology and Evolution, published by Oxford University Press, finds that the relatively high rate of Autism-spectrum disorders in humans is likely due to how humans evolved in the past. About one in 31 (3.2%) children in the United States has been identified with Autism Spectrum Disorder. Globally, the World Health Organization estimates that around one in 100 children have autism. From an evolutionary perspective, many scientist believe that autism and schizophrenia may be unique to humans. ...

Swedish psychologist transforms mental health access through digital therapy revolution

2025-09-09
LINKÖPING, SWEDEN, 9 September 2025 -- In a revealing Genomic Press Interview published today in Genomic Psychiatry, Dr. Gerhard Andersson traces his extraordinary journey from skateboarding punk musician to becoming the architect of a global revolution in psychological treatment delivery. The comprehensive interview unveils how two graduate students knocking on his office door in 1998 sparked a transformation that would fundamentally alter how millions access mental healthcare worldwide. From Uppsala Laboratory to Global Impact Dr. Andersson's path to scientific prominence began unexpectedly ...

Centenarian neuroscientist inspires blueprint for vibrant longevity through mentorship and connection

2025-09-09
TUCSON, Arizona, USA, 9 September 2025 -- A viewpoint article published today in Brain Medicine by Dr. Esther Sternberg provides a compelling portrait of how one pioneering neuroscientist continues to thrive beyond his centennial year. The tribute to Dr. Seymour Reichlin, published as part of a special Festschrift commemorating his 100th birthday, examines the multifaceted elements that have sustained his remarkable intellectual vigor and social vitality at 101 years old. Dr. Sternberg, who has directed research at the Andrew Weil Center for Integrative ...

King’s College London researcher advances psychiatric genomics through pioneering polygenic scoring innovations

2025-09-09
LONDON, England, UNITED KINGDOM, 9 September 2025 -- In a compelling Genomic Press Interview published today in Genomic Psychiatry, Dr Oliver Pain reveals how personal experiences and scientific curiosity converged to reshape global approaches to psychiatric genomics. The Sir Henry Wellcome Postdoctoral Research Fellow transforms how scientists worldwide understand and apply genetic risk prediction for mental health disorders, developing tools that democratize access to cutting-edge genomic methodologies across international research communities. The interview illuminates Dr Pain's evolution ...

Study questions ocean origin of organics in Enceladus’s plumes

2025-09-09
Organic molecules detected in the watery plumes that spew out from cracks in the surface of Enceladus could be formed through exposure to radiation on Saturn’s icy moon, rather than originating from deep within its sub-surface ocean. The findings, presented during the EPSC–DPS2025 Joint Meeting in Helsinki this week, have repercussions for assessing the habitability of Enceladus’s ocean. ‘While the identification of complex organic molecules in Enceladus’s environment remains an important clue in assessing the moon’s habitability, the results demonstrate that radiation-driven chemistry ...

LAST 30 PRESS RELEASES:

Scientists create ChatGPT-like AI model for neuroscience to build one of the most detailed mouse brain maps to date

AI and omics unlock personalized drugs and RNA therapies for heart disease

2023 ocean heatwave ‘unprecedented but not unexpected’

Johns Hopkins researchers develop AI to predict risk of US car crashes

New drug combination offers hope for men with advanced prostate cancer

New discovery finds gene converts insulin-producing cells into blood-sugar boosters

Powerful and precise multi-color lasers now fit on a single chip

Scientists agree chemicals can affect behavior, but industry workers more reluctant about safety testing

DNA nanospring measures cellular motor power

Elsevier Foundation and RIKEN launch “Envisioning Futures” report: paving the way for gender equity and women’s leadership in Japanese research

Researchers discover enlarged areas of the spinal cord in fish, previously found only in four-limbed vertebrates

Bipolar disorder heterogeneity decoded: transforming global psychiatric treatment approaches

Catching Alport syndrome through universal age-3 urine screening

Instructions help you remember something better than emotions or a good night’s sleep

Solar energy is now the world’s cheapest source of power, a Surrey study finds

Scientists reverse Alzheimer’s in mice using nanoparticles

‘Good’ gut bacteria boosts placenta for healthier pregnancy

USC team demonstrates first optical device based on “optical thermodynamics”

Microplastics found to change gut microbiome in first human-sample study

Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds

Plastic in the soil, but not as we know it: Biodegradable microplastics rewire carbon storage in farm fields

Yeast proteins reveal the secrets of drought resistance

Psychiatry, primary care, and OB/GYN subspecialties hit hardest by physician attrition

New Canadian study reveals where HIV hides in different parts of the body

Lidocaine poisonings rise despite overall drop in local anesthetic toxicity

Politics follow you on the road

Scientists blaze new path to fighting viral diseases

The mouse eye as a window to spotting systemic disease

AI and the Future of Cancer Research and Cancer Care to headline October 24 gathering of global oncology leaders at the National Press Club: NFCR Global Summit to feature top scientists, entrepreneurs

FDA clears UCLA heart tissue regeneration drug AD-NP1 for clinical trials

[Press-News.org] “Bottlebrush” particles deliver big chemotherapy payloads directly to cancer cells
Outfitted with antibodies that guide them to the tumor site, the new nanoparticles could reduce the side effects of treatment.